Fiala

Peptide library › Metabolic & weight

Petrelintide

In clinical trialsMetabolic & weight

Experimental long-acting amylin analog given weekly for weight loss, aiming for fewer stomach side effects than GLP-1 drugs.

What people use it for

What Petrelintide does in the body

Mimics amylin, a hormone released with insulin after meals that makes you feel full sooner. Amylin works on different brain pathways from GLP-1, which may mean gentler side effects.

Strength of evidence

Moderate: early trials and a positive Phase 2 trial in obesity. Phase 3 results are not yet available.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

Investigational. Not approved by the FDA or any regulator.

How it's taken

Route: Injection under the skin, once weekly (in trials)

How long it lasts (half-life): Long-acting; designed for weekly dosing

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Petrelintide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Petrelintide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Metabolic & weight